Literature DB >> 32463538

Excess out-of-hospital deaths during the COVID-19 outbreak: evidence of pulmonary embolism as a main determinant.

Joseph Benzakoun1,2,3, Ghazi Hmeydia1,2, Tania Delabarde4,5,6, Lilia Hamza5,6, Jean-François Meder1,2,3, Bertrand Ludes3,4,5,6, Alexandre Mebazaa3,7,8.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32463538      PMCID: PMC7283748          DOI: 10.1002/ejhf.1916

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   17.349


× No keyword cloud information.
Coronavirus disease 2019 (COVID‐19) deteriorates pulmonary function and can lead to acute hypoxaemic respiratory failure. COVID‐19 may also directly impact the cardiovascular system. Cases of pulmonary embolism (PE) were reported in in‐hospital settings , , , and in a small post‐mortem autopsy series. Our study investigates the relation between PE and out‐of‐hospital unexplained death during COVID‐19 outbreak. The Institute of Forensic Medicine of Paris (IFMP) regularly performs unenhanced post‐mortem computed tomography (PMCT) on deceased subjects upon judicial request to investigate death causes. The study objective was to compare proximal PE rate on PMCT between subjects suspected of COVID‐19 during the outbreak peak in Paris (from 23 March to 7 April 2020, COVID‐19‐suspected group) and subjects scanned during 2019 (control group). We analysed ≥18‐year‐old subjects presenting unexplained death explored with PMCT, excluding traumas and putrefied bodies. During the COVID‐19 outbreak peak, only subjects who were suspected to have contracted COVID‐19 were included. As virologic tests were not performed due to prioritization of reverse‐transcriptase polymerase chain reaction tests to living patients, the COVID‐19‐suspected status was determined following clinical context and lung computed tomography abnormalities which have demonstrated a high diagnostic value. Thoracic and limb PMCTs were blindly read by two experts and disagreements were solved in consensus. Proximal PE and deep vein thrombosis (DVT) were defined according to previous study criteria. In accordance with French legislation, Ethics Committee approval was not needed for this retrospective, non‐interventional study; commitment to compliance was filed (Reference Methodology MR‐004, no. 2617140420). Statistical analysis was performed with R software, using Fisher and Mann–Whitney U tests for comparisons, and logistic regression to adjust odds ratio (OR) on age and sex. Results are expressed as median and interquartile range (IQR). The unexplained death rate was strikingly higher during COVID‐19 outbreak peak [68 (79%) of 86 deaths] than during the control year 2019 [70 (21%) of 334 deaths; OR 14.1, P < 0.001]. Among the 68 subjects with unexplained death during COVID‐19 outbreak peak, four without pulmonary COVID‐19 lesions were excluded. COVID‐19‐suspected subjects (n = 64) were older (65 years, IQR 56–73, range 27–99) than control subjects (n = 70, 55 years, IQR 40–65, range 19–91, P = 0.0003). Sex ratio was not significantly different between groups [49/64 (77%) vs. 49/70 (70%) men, P = 0.44]. Most of the COVID‐19‐suspected subjects died at home, some presented with fever and/or cough before death, and the majority had suddenly lost contact with health care providers and/or family members 30 min to several hours earlier. The proximal PE rate was higher in the COVID‐19‐suspected group than in the control group [15/64 (23%) vs. 5/70 (7%), P = 0.014] (Figure ). This was confirmed after adjustment on age and gender (OR 3.9, 95% confidence interval 1.3–13.4, P = 0.017). In subjects whose lower limbs were explored (50/64 COVID‐19‐suspected and all control subjects), the DVT rate was higher in the COVID‐19‐suspected group than in the control group [9/50 (18%) vs. 3/70 (4%), P = 0.026] (Figure ).
Figure 1

Comparison of pulmonary embolism and deep vein thrombosis rate in unexplained deaths between subjects scanned during the year 2019 (control group) and in COVID‐19‐suspected patients during the 2‐week outbreak peak (COVID‐19 group). Presence of deep vein thrombosis was evaluated only in subjects who underwent limb computed tomography.

Comparison of pulmonary embolism and deep vein thrombosis rate in unexplained deaths between subjects scanned during the year 2019 (control group) and in COVID‐19‐suspected patients during the 2‐week outbreak peak (COVID‐19 group). Presence of deep vein thrombosis was evaluated only in subjects who underwent limb computed tomography. Our study showed that during the COVID‐19 Paris outbreak, the IFMP diagnosed threefold more proximal PE in unexplained death that in the entire year 2019. Moreover, the unexplained death rate was high and strikingly associated with COVID‐19‐related pulmonary PMCT lesions during the outbreak. Our findings have several clinical implications. First, we confirm that COVID‐19 is associated with unexplained death, highlighting the need for personal protective equipment for the resuscitation of an unexplained death during the outbreak. Second, the high PE rate in our unexplained death series implies that it is a frequent cause of cardiac arrest, urging the resuscitated patient to be transferred to a cardiogenic shock centre. Third, our results strongly suggest that PE should be explored in severe COVID‐19 patients admitted to hospitals in order to start appropriate anticoagulation and to prevent death.
  8 in total

1.  Pulmonary thromboembolism on unenhanced postmortem computed tomography: Feasibility and findings.

Authors:  Garyfalia Ampanozi; Ulrike Held; Thomas D Ruder; Steffen G Ross; Wolf Schweitzer; Juergen Fornaro; Sabine Franckenberg; Michael J Thali; Patricia M Flach
Journal:  Leg Med (Tokyo)       Date:  2016-04-19       Impact factor: 1.376

2.  Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography.

Authors:  Franck Grillet; Julien Behr; Paul Calame; Sébastien Aubry; Eric Delabrousse
Journal:  Radiology       Date:  2020-04-23       Impact factor: 11.105

3.  Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.

Authors:  Tao Ai; Zhenlu Yang; Hongyan Hou; Chenao Zhan; Chong Chen; Wenzhi Lv; Qian Tao; Ziyong Sun; Liming Xia
Journal:  Radiology       Date:  2020-02-26       Impact factor: 11.105

4.  Myocardial localization of coronavirus in COVID-19 cardiogenic shock.

Authors:  Guido Tavazzi; Carlo Pellegrini; Marco Maurelli; Mirko Belliato; Fabio Sciutti; Andrea Bottazzi; Paola Alessandra Sepe; Tullia Resasco; Rita Camporotondo; Raffaele Bruno; Fausto Baldanti; Stefania Paolucci; Stefano Pelenghi; Giorgio Antonio Iotti; Francesco Mojoli; Eloisa Arbustini
Journal:  Eur J Heart Fail       Date:  2020-04-11       Impact factor: 15.534

5.  Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Authors:  Gian Battista Danzi; Marco Loffi; Gianluca Galeazzi; Elisa Gherbesi
Journal:  Eur Heart J       Date:  2020-05-14       Impact factor: 29.983

6.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.

Authors:  Dominic Wichmann; Jan-Peter Sperhake; Marc Lütgehetmann; Stefan Steurer; Carolin Edler; Axel Heinemann; Fabian Heinrich; Herbert Mushumba; Inga Kniep; Ann Sophie Schröder; Christoph Burdelski; Geraldine de Heer; Axel Nierhaus; Daniel Frings; Susanne Pfefferle; Heinrich Becker; Hanns Bredereke-Wiedling; Andreas de Weerth; Hans-Richard Paschen; Sara Sheikhzadeh-Eggers; Axel Stang; Stefan Schmiedel; Carsten Bokemeyer; Marylyn M Addo; Martin Aepfelbacher; Klaus Püschel; Stefan Kluge
Journal:  Ann Intern Med       Date:  2020-05-06       Impact factor: 25.391

7.  End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV.

Authors:  Nianguo Dong; Jie Cai; Ying Zhou; Junwei Liu; Fei Li
Journal:  JACC Heart Fail       Date:  2020-04-07       Impact factor: 12.035

8.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

  8 in total
  10 in total

1.  Right Ventricular Clot in Transit in a Patient with Coronavirus Disease 2019 (COVID-19) Pneumonia Successfully Treated with Thrombolytics.

Authors:  Yaman Alali; Ian Jackson; Abedel Rahman Anani; Marisa Varghese; Muhammad Ebrahim Khan; Suchitra Pilli
Journal:  Case Rep Crit Care       Date:  2022-07-05

Review 2.  SARS-CoV-2 Infection and the Kidneys: An Evolving Picture.

Authors:  Jaya A George; Siyabonga Khoza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.

Authors:  Julie Goswami; Taleen A MacArthur; Meera Sridharan; Rajiv K Pruthi; Robert D McBane; Thomas E Witzig; Myung S Park
Journal:  Shock       Date:  2021-06-01       Impact factor: 3.533

4.  Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis.

Authors:  Robert M Kwee; Hugo J A Adams; Thomas C Kwee
Journal:  Eur Radiol       Date:  2021-05-09       Impact factor: 5.315

5.  Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis.

Authors:  Mahmoud B Malas; Isaac N Naazie; Nadin Elsayed; Asma Mathlouthi; Rebecca Marmor; Bryan Clary
Journal:  EClinicalMedicine       Date:  2020-11-20

6.  Thromboprophylaxis strategies to improve the prognosis of COVID-19.

Authors:  Laurent Bertoletti; Behnood Bikdeli; Stéphane Zuily; Marc Blondon; Patrick Mismetti
Journal:  Vascul Pharmacol       Date:  2021-06-04       Impact factor: 5.773

7.  Complications and mortality of cardiovascular emergency admissions during COVID-19 associated restrictive measures.

Authors:  Heiko Bugger; Johannes Gollmer; Gudrun Pregartner; Gerit Wünsch; Andrea Berghold; Andreas Zirlik; Dirk von Lewinski
Journal:  PLoS One       Date:  2020-09-24       Impact factor: 3.240

8.  Making things right! Shouldn't we screen patients with thromboembolic events for SARS-CoV-2 infection, during the pandemia?

Authors:  C de Roquetaillade; B G Chousterman; A Mebazaa
Journal:  Int J Cardiol       Date:  2021-03-29       Impact factor: 4.164

Review 9.  Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.

Authors:  Benjamin Marchandot; Antonin Trimaille; Anais Curtiaud; Kensuke Matsushita; Laurence Jesel; Olivier Morel
Journal:  J Thromb Thrombolysis       Date:  2020-11       Impact factor: 5.221

10.  Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London.

Authors:  Antonio Cannatà; Daniel I Bromage; Irfan A Rind; Caterina Gregorio; Clare Bannister; Mohammed Albarjas; Susan Piper; Ajay M Shah; Theresa A McDonagh
Journal:  Eur J Heart Fail       Date:  2020-09-28       Impact factor: 17.349

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.